CAR-T Cell Therapy at 2BScientific Limited
Chimeric Antigen Receptor T-cell (CAR-T) therapy is an innovative method of immunotherapy that uses the patient's own immune cells to target and eliminate cancer cells. This is carried out by genetically modifying T-cells to express receptors that recognise cancer-specific antigens. CAR-T therapy has proven particularly effective for hematologic cancers such as B-cell lymphomas and acute lymphoblastic leukaemia. It offers highly targeted cancer treatment with the potential for long-term remission.
CAR-T therapy begins with the collection of T-cells from the patient through a process called leukapheresis. The collected T-cells are then genetically engineered to express a Chimeric Antigen Receptor (CAR) on their surface. This CAR enables the T-cells to specifically recognise and bind to antigens found on cancer cells, such as CD19, which is commonly expressed in B-cell malignancies.
Once the T-cells are engineered, they are expanded in the laboratory and infused back into the patient. Upon infusion, these CAR-modified T-cells can identify and attack cancer cells, leading to their destruction. Importantly, CAR-T cells are designed to proliferate and persist in the patient's body, offering a sustained immune response against the cancer.
CAR-T cell therapy has additionally demonstrated effective in treating patients with relapsed or refractory blood cancers, particularly in cases where other treatments have failed. These therapies target malignancies and have demonstrated high response rates and durable remissions in clinical trials.
Recent advances are also exploring the use of CAR-T cells in solid tumours, though this remains more challenging due to the complex tumour microenvironment and the lack of ideal antigens that are exclusively expressed on solid tumour cells. Despite these challenges, researchers are actively investigating novel CAR designs, including dual-targeted CARs and logic-gated CARs, to enhance their specificity and efficacy in solid tumours.
2BScientific Limited understands the complexities of CAR-T cell therapy and aims to assist in advancing this approach. While there are ongoing challenges, particularly in the areas of safety, accessibility, and the treatment of solid tumours, and we are here to support that and work towards ideal, tailored solutions.